Clinical Trial Update: Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial update of Anecortave Acetate for subfoveal choroidal neovascularization due to wet age-related macular degeneration; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Alcon Research | Conditions: Macular Degeneration, Maculopathy, Age-Related | Phase 3 | Status: COMPLETED